{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T14:55:23Z","timestamp":1780671323144,"version":"3.54.1"},"reference-count":17,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2006,9,1]],"date-time":"2006-09-01T00:00:00Z","timestamp":1157068800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2006,9,1]],"date-time":"2006-09-01T00:00:00Z","timestamp":1157068800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2006,9]]},"DOI":"10.1016\/j.jaad.2006.05.018","type":"journal-article","created":{"date-parts":[[2006,7,26]],"date-time":"2006-07-26T01:21:03Z","timestamp":1153876863000},"page":"442-448","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["A risk management program aimed at preventing fetal exposure to isotretinoin: Retrospective cohort study"],"prefix":"10.1016","volume":"55","author":[{"given":"T. Craig","family":"Cheetham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gene","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer M.","family":"Day","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica A.","family":"Yoshinaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2006.05.018_bib1","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1001\/archotol.125.12.1385","article-title":"Multiple temporal bone anomalies in isotretinoin syndrome: a temporal bone histopathologic case report","volume":"125","author":"Ishijima","year":"1999","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.jaad.2006.05.018_bib2","unstructured":"Pitts M. (FDA). Joint Advisory Committee Meeting with Drug Safety and Risk Management Panel plus Dermatologic and Ophthalmic Drugs Panel, February 26, 2004. Available at: http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/04\/slides\/4017S1_06_Pitts.ppt. Accessed December 14, 2005."},{"key":"10.1016\/j.jaad.2006.05.018_bib3","first-page":"78","article-title":"Isotretinoin (Ro-Accutane) teratogenesis. A case report","volume":"32","author":"Giannoulis","year":"2005","journal-title":"Clin Exp Obstet Gynecol"},{"key":"10.1016\/j.jaad.2006.05.018_bib4","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.jaapos.2004.12.017","article-title":"Congenital oculomotor nerve synkinesis associated with fetal retinoid syndrome","volume":"9","author":"Morrison","year":"2005","journal-title":"J AAPOS"},{"key":"10.1016\/j.jaad.2006.05.018_bib5","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1056\/NEJM199507133330206","article-title":"A pregnancy-prevention program in women of childbearing age receiving isotretinoin","volume":"333","author":"Mitchell","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2006.05.018_bib6","unstructured":"Dermatologic and Ophthalmic Drugs Advisory Committee [agenda], September 18 and 19, 2000, Gaithersburg, MD. Available at: http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/00\/agenda\/3639a1.doc. Accessed December 14, 2005."},{"key":"10.1016\/j.jaad.2006.05.018_bib7","unstructured":"Lindstrom J (FDA). Joint Advisory Committee Meeting with Drug Safety and Risk Management Panel plus Dermatologic and Ophthalmic Drugs Panel. February 26, 2004. Available at: http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/04\/slides\/4017S1_01_Linstrom.ppt. Accessed December 15, 2005."},{"key":"10.1016\/j.jaad.2006.05.018_bib8","unstructured":"Huber M (Roche). Joint Advisory Committee Meeting with Drug Safety and Risk Management Panel plus Dermatologic and Ophthalmic Drugs Panel. February 26, 2004. Available at: http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/04\/slides\/4017S1_02_Roche.ppt. Accessed December 14, 2005."},{"key":"10.1016\/j.jaad.2006.05.018_bib9","unstructured":"Brinker A. (FDA). Joint Advisory Committee Meeting with Drug Safety and Risk Management Panel plus Dermatologic and Ophthalmic Drugs Panel. February 26, 2004. Available at: http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/04\/slides\/4017S1_07_Brinker.ppt. Accessed December 14, 2005."},{"key":"10.1016\/j.jaad.2006.05.018_bib10","unstructured":"Presentation by Hoffmann-La Roche, Inc. Joint Advisory Committee Meeting with Drug Safety and Risk Management Panel plus Dermatologic and Ophthalmic Drugs Panel. February 26, 2004. Available at: http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/04\/slides\/4017S1_02_Roche.ppt. Accessed December 14, 2005."},{"key":"10.1016\/j.jaad.2006.05.018_bib11","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/j.1479-828X.1995.tb02157.x","article-title":"Terminations of pregnancy for exposure to oral retinoids in South Australia, 1985-1993","volume":"35","author":"Chan","year":"1995","journal-title":"Aust N Z J Obstet Gynaecol"},{"key":"10.1016\/j.jaad.2006.05.018_bib12","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1002\/tera.1057","article-title":"Continued occurrence of Accutane-exposed pregnancies","volume":"64","author":"Honein","year":"2001","journal-title":"Teratology"},{"key":"10.1016\/j.jaad.2006.05.018_bib13","first-page":"28","article-title":"Accutane-exposed pregnancies California 1999","volume":"49","author":"Centers for Disease Control and Prevention (CDC)","year":"2000","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.jaad.2006.05.018_bib14","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1002\/bdra.20197","article-title":"A survey of pregnant women using isotretinoin","volume":"73","author":"Robertson","year":"2005","journal-title":"Birth Defects Res Clin Mol Teratol"},{"key":"10.1016\/j.jaad.2006.05.018_bib15","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1001\/archderm.141.5.563","article-title":"Trends in adherence to a revised risk management program designed to decrease of eliminate isotretinoin-exposed pregnancies: evaluation of the Accutane SMART program","volume":"141","author":"Brinker","year":"2005","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2006.05.018_bib16","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/pds.1111","article-title":"Changes in isotretinoin prescribing before and after implementation of the System to Manage Accutane Related Teratogenicity (SMART) risk management program","volume":"14","author":"Mendelsohn","year":"2005","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.jaad.2006.05.018_bib17","unstructured":"iPLEDGE program announcement \u2014 FDA. Available at; http:\/\/www.fda.gov\/cder\/drug\/advisory\/isotretinoin2005.htm. Accessed December 14, 2005."}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962206014903?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962206014903?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:02:48Z","timestamp":1759269768000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962206014903"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,9]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2006,9]]}},"alternative-id":["S0190962206014903"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2006.05.018","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2006,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A risk management program aimed at preventing fetal exposure to isotretinoin: Retrospective cohort study","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2006.05.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2006 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}